加载中
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
收盘时
US$0.28
−US$0.014 · -4.76%
盘后
US$0.2834
+US$0.0034 · +1.21%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
日内区间
当前US$0.28
52周区间
当前US$0.28
盘中时间采用ET。市场数据可能有所延迟。
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
日内区间
当前US$0.28
52周区间
当前US$0.28
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 389.2万 USD | 1124万 USD |
| 销货成本 | — | 25.9万 USD | 30.3万 USD | 256万 USD | 409.7万 USD |
| 毛利 | — | −25.9万 USD | −30.3万 USD | 133.2万 USD | 714.3万 USD |
| 研究与开发 | 1878万 USD | 2183.5万 USD | 1858.6万 USD | 1765.3万 USD | 1151.5万 USD |
| 销售、一般及管理费用 | 2362.9万 USD | 1834万 USD | 2026.4万 USD | 6503.5万 USD | 1.05亿 USD |
| 营业费用 | 3916.1万 USD | 4017.5万 USD | 3885万 USD | 8268.8万 USD | 1.17亿 USD |
| 利息收入 | 114万 USD | 205.6万 USD | 271.1万 USD | 66.4万 USD | 10.4万 USD |
| 利息支出 | 327.6万 USD | 578.3万 USD | 581.4万 USD | 726.6万 USD | 838万 USD |
| 折旧和摊销 | 31.7万 USD | 25.9万 USD | 30.3万 USD | 53.7万 USD | 97.5万 USD |
| 营业利润 | −3916.1万 USD | −4043.4万 USD | −3915.3万 USD | −8135.6万 USD | −1.09亿 USD |
| 净利润 | −2698万 USD | −3851.1万 USD | −4219.9万 USD | −4482.2万 USD | −1.43亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$18.25
上涨空间 6417.86%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年5月11日 | 1:50 | — | — |
股票拆分 | 2022年10月21日 | 1:50 | — | — |
股票拆分 | 2022年8月26日 | 2:1 | — | — |
已生效 2026年5月11日
1:50
已生效 2022年10月21日
1:50
已生效 2022年8月26日
2:1
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
